Balaglitazone, also known as DRF-2593; NNC-61-0645; NNC-61-2344; NN-2344; NNC-610645; NNC-612344, is an agonist of peroxisome proliferator-activated receptor (PPAR)γ. Balaglitazone plays an important role in the regulation of insulin, triglycerides and lipid metabolism. It is an attractive target for the therapy of Type II Diabetes. Balaglitazone is a partial agonist of PPARγ. It has showed potent effects on lowering blood glucose in various animal models. Balaglitazone passed phase III clinical trial for the treatment of type 2 diabetes. However, Dr. Reddy's Laboratories decided to terminate further clinical development of balaglitazone. Balaglitazone exists as two enantiomers: BALAGLITAZONE, (S)- and BALAGLITAZONE, (R)-. A capillary electrophoresis method for separation of a racemic mixture of glitazone compounds has being used. The method separated the R and S enantiomers of balaglitazone, and showed that the samples contained an equal (50:50) quantity of the enantiomers as a mixture. The Rs for the separations were 3.5 for balaglitazone enantiomers.

Quebrachitol (QCT), a bioactive plant constituent, is a naturally occurring optically active cyclitols. QCT could serve as the starting material of inositol or its derivatives to participate in several important pathways and may act as a potential anticancer or antidiabetic drug lead to arrest or reverse these diseases. According to the literature reported before, QCT exerted its biological functions, by involving IP3 receptor, b-glucosidase, PAFR, COX2, nitric oxide synthase, and K(+)ATP channels. Quebrachitol reduces the gastric damage induced by ethanol and indomethacin. The potential of quebrachitol as a sugar substitute for diabetics has been investigated. Even though the early study reported that this methylcyclitol seems neither to prevent hypoglycemia nor to raise blood sugar content, another work showed that quebrachitol has hypoglycemic effects in hyperglycemic rats. Unfortunately, all three persons who took quebrachitol by mouth had fairly severe diarrhea.

Balaglitazone, also known as DRF-2593; NNC-61-0645; NNC-61-2344; NN-2344; NNC-610645; NNC-612344, is an agonist of peroxisome proliferator-activated receptor (PPAR)γ. Balaglitazone plays an important role in the regulation of insulin, triglycerides and lipid metabolism. It is an attractive target for the therapy of Type II Diabetes. Balaglitazone is a partial agonist of PPARγ. It has showed potent effects on lowering blood glucose in various animal models. Balaglitazone passed phase III clinical trial for the treatment of type 2 diabetes. However, Dr. Reddy's Laboratories decided to terminate further clinical development of balaglitazone. Balaglitazone exists as two enantiomers: BALAGLITAZONE, (S)- and BALAGLITAZONE, (R)-. A capillary electrophoresis method for separation of a racemic mixture of glitazone compounds has being used. The method separated the R and S enantiomers of balaglitazone, and showed that the samples contained an equal (50:50) quantity of the enantiomers as a mixture. The Rs for the separations were 3.5 for balaglitazone enantiomers.

Genz-123346 is a potent and selective glucosylceramide synthase (GCS) inhibitor that blocks the conversion of ceramide to GL1. It has been studied as a potential treatment of diabetes mellitus, polycystic kidney disease and fatty liver disease. Genz-123346 improved glucose tolerance and increased insulin sensitivity in two animal models of type 2 diabetes. In Zucker diabetic fatty rats, treatment with Genz-123346 significantly lowered blood glucose levels and partially prevented the normal deterioration of pancreatic β-cell function over time and preserved the ability of the islets to secrete insulin. In the high-fat–fed diet-induced obese mice, Genz-123346 essentially normalized A1C levels to that of the lean animals. Inhibiting GSL synthesis ameliorates the liver pathology associated with obesity and diabetes in mice model. Blockade of kidney glucosylceramide GlcCer accumulation with the GCS inhibitor Genz-123346 effectively inhibits cystogenesis in mouse models orthologous to human autosomal dominant polycystic kidney disease (PKD) (Pkd1 conditional knockout mice) and nephronophthisis (jck and pcy mice). Molecular analysis in vitro and in vivo indicated that inhibition of GCS by Genz-123346 inhibited the AKT-mTOR signaling pathway. It induced autophagy via the AKT-mTOR signaling pathway in HEK293T cells, increased autophagy flux and reduced mutant α-syn levels in mouse primary neurons potentially via indendent mechanisms. Exposure of cells to Genz-123346 and to other GCS inhibitors at non-toxic concentrations can enhance the killing of tumor cells by cytotoxic anti-cancer agents. This chemosensitizing activity was unrelated to lowering intracellular glycosphingolipid levels. Genz-123346 is a substrate for multi-drug resistance efflux pumps such as P-gp (ABCB1, gP-170). In cell lines selected to over-express P-gp or which endogenously express P-gp, chemosensitization by Genz-123346 was primarily due to the effects on P-gp function. Genz-123346 has little effect on 1-O-acylceramide synthase activity at concentrations that effectively inhibit GL1 synthase activity and therefore do not significantly elevate cell ceramide levels in vitro. Unlike N-butyldeoxynojirimycin (NB-DNJ), another inhibitor of GCS Genz-123346 does not inhibit α-glucosidase or glucocerebrosidase.

Corosolic acid is a pentacyclic triterpene acid isolated from Lagerstroemia speciosa. It inhibits STAT3 and VEGFR2 signaling and has cytotoxic effect on a number of tumor cell lines. Corosolic acid has demonstrated anti-diabetic effect in vivo, probably due to facilitation of GLUT4 translocation or AMPK activation.

CP-91149 is a selective glycogen phosphorylase (GP) inhibitor in the presence of glucose, 5- to 10-fold less potent in the absence of glucose. It may be useful in the treatment of type 2 diabetes. In vivo, oral injection of CP-91149 to diabetic ob/ob mice at 25–50 mg/kg led in rapid (3 h) glucose lowering by 100–120 mg/dl without producing hypoglycemia. In addition, upon treatment with CP-91149, A549 non-small cell lung carcinoma (NSCLC) cells accumulated glycogen with associated growth retardation. Treated normal skin fibroblasts also accumulated glycogen with G1-cell cycle arrest that was associated with inhibition of cyclin E-CDK2 activity

K-579 ((S)-1-[4-methyl-1-(2-pyrimidinyl)-4-piperidylamino]acetyl-2-pyrrolidinecarbonitrile) is potent and slower binding dipeptidyl peptidase IV inhibitor which was investigated as an antidiabetic drug. K579 suppressed the blood glucose elevation after an oral glucose tolerance test with the increment of plasma insulin and active forms of Glucagon-like peptide-1 (GLP-1). During repetitive glucose loading using Zucker fatty rats, pretreatment with K579 attenuated the glucose excursion after the second glucose loading as well as the first glucose loading without inducing hypoglycemia.

Genipin is an aglycone derived from an iridoid glycoside called Geniposide (structure on the bottom) present in fruit of Gardenia jasmindides Ellis. Genipin have been demonstrated to have diverse pharmacological activities including anti-inflammatory, antioxidative, neuroprotective, and neurotrophic effects. Genipin is an excellent natural cross-linker for protein, collagen, gelatin, and chitosan cross-linking and can be considered as a substitute for glutaraldehyde. Due to cross-linking properties genipin can be used in controlling drug delivery. In addition genipin exerts choleretic action.

PF-915275 is a potent and selective 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) inhibitor (Ki = 2.3 nM) PF-915275 inhibits the conversion of prednisone to prednisolone in human hepatocytes in vitro (EC50 = 15 nM) and has antidiabetic activity in vivo. In first half 2007, Pfizer stopped developing PF 915275 for the treatment of type II diabetes mellitus.

Gramine (aka donaxine) is a naturally occurring indole alkaloid that can be found in several plant species. It is toxic to many organisms and may be a natural defense mechanism for these plants. Gramine has been found to act as an agonist of the adiponectin receptor 1 (AdipoR1) which plays an important role in the suppression of metabolic disorders that can result in type 2 diabetes, obesity, and atherosclerosis.